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Edited by Vladimir SkulachevAbstract We have investigated the radioprotective eﬃcacy of
eckol, a component of brown seaweed Ecklonia cava, against
the gamma ray-induced damage in vivo. Our results showed that
eckol signiﬁcantly decreased the mortality of lethally irradiated
mice. The mechanisms of eckols protection were found to in-
clude: an improvement in hematopoietic recovery, the repair of
damaged DNA in immune cells and an enhancement of their pro-
liferation, which had been severely suppressed by ionizing radia-
tion. Thus, we propose eckol as a candidate for adjuvant therapy
to alleviate radiation-induced injuries to cancer patients.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Exposure to ionizing radiation induces the production of
reactive oxygen species (ROS), which include superoxide, hy-
droxyl radicals, singlet oxygen, and hydrogen peroxide [1].
These free radicals react with critical cellular components, such
as DNA, RNA, proteins, and membranes resulting in cell dys-
function and death [2]. Recently, the synthetic agents WR2721
(amifostine), OK-432, and ethiofos were investigated for their
eﬃcacy in protecting against radiation-induced tissue damage
[3]. However, these agents have the potential cause serious
side-eﬀects including decreased cellular function, nausea,
hypotension, and death [4,5]. Alternatively, natural plant ex-
tracts that can protect cells and tissues against ionizing radia-
tion without obvious side-eﬀects would be a considerable
adjunct to successful radiotherapy.
Ecklonia cava, brown algae (Laminariaceae) abundant
around Jeju Island in Korea, contains phlorotannin compo-
nents with known biological activities [6,7]. Phlorotannin has
anti-inﬂammatory eﬀects [6] and protects cells from oxidativeAbbreviations: CFU, colony-forming unit; FITC, ﬂuorescein isothio-
cyanate; Gy, gray; FACS, ﬂuorescence-activated cell sorting; ROS,
reactive oxygen species; WBI, whole-body irradiation; Con A, conca-
navalin A
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which is a phloroglucinol polymer found in marine algal poly-
phenols, has been identiﬁed in various Ecklonia species [8]. We
previously reported that eckol inhibits oxidative cell damage
by scavenging ROS and modulating a cellular signal pathway
in lung ﬁbroblast cells [8]. To extend these results, we tested
eckol in an E. cava extract for the ability to protect mice from
radiation-induced oxidative damage in vivo after exposure to a
single dose of whole-body irradiation (WBI) in vivo.2. Materials and methods
2.1. Preparation of eckol and irradiation of animals with 60Co c-ray
Eckol (Fig. 1) was obtained as described previously [8]. C57BL/6
mice (Orientbio, Sungnam, Korea) weighing 18–25 g each were used
at 6–8 weeks of age for these experiments. These mice were housed
in conventional animal facilities with the NIH-07-approved diet and
water ad libitum at a constant temperature (23 ± 1 C) according to
the guidelines for the Care and Use of Laboratory Animals of the insti-
tutional ethics committee. Each mouse was placed individually in a
close-ﬁtting Perspex box (3 · 3 · 11 cm) and exposed to WBI with a
60Co source irradiator (Theratron-780 Teletherapy Unit, Applied
Radiological Science Institute, Cheju National University). Brieﬂy,
mice placed in the box were exposed to WBI with a dose rate of
1.5 Gy/min and source-surface distance of 150 cm, as previously
reported [9,10].2.2. Treatment of mice with eckol and survival studies
Eckol dissolved in phosphate-buﬀered saline (PBS, pH 7.4) was used
at a dose of 10 mg/kg b.w. for intraperitoneal (i.p.) injection into the
mice. The choice of this dose was inspired by the fact that, the survival
rates were 86%, 86.6%, and 40%, respectively, when mice were treated
with eckol at concentrations of 25, 10 or 5 mg/kg body weight (b.w.)
after 9 Gy of irradiation whereas a survival rate of only 28.6% was ob-
served in the irradiated control mice. Each mouse was injected twice,
receiving the 10 mg/kg dose ﬁrst at 18 h and then again at 2 h before
irradiation. Additional non-irradiated and irradiated groups of mice
were injected i.p. with PBS at the same volumes. The mice were ran-
domly divided into the following four groups: (1) non-irradiated nor-
mal group; (2) irradiated control group; (3) eckol-treated group; (4)
eckol plus irradiation-treated group. To determine whether eckol con-
ferred a survival advantage after lethal WBI, the treated mice were ob-
served daily for up to 30 days after irradiation. At 31 days post-WBI,
the surviving mice were killed by cervical dislocation.2.3. Blood sample collection and quantitation of eckol
The time required to attain the maximum concentration (Tmax) and
terminal half life (t1/2) was determined by collecting blood samples from
mice into heparinized tubes at 0.5, 1, 2, 6, and 24 h after treatment withblished by Elsevier B.V. All rights reserved.
Fig. 1. The chemical structure of eckol.
Table 1





9 Gy IR (n = 14) 28.6 ± 13.5 19.0 ± 7.9
9 Gy IR plus eckol (n = 15) 86.6 ± 6.0 27.3 ± 7.2*
Mice were injected with i.p. with eckol (10 mg/kg b.w.) 2 and 18 h
before being exposed to 9 Gy of WBI. The term n represents the total
number of mice in each group. The results shown are the means ± S.D.
of three independent experiments. Diﬀerences in the 30-day survival
rates were calculated with the Students t-test.
*P < 0.05.
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for 10 min. The resultant plasma was mixed with one-tenth volume of
a preservative solution that contained 20% ascorbic acid and 0.05%
Na2EDTA in 0.4 M sodium phosphate buﬀer (pH 7.2). The level of
eckol in the plasma was determined by HPLC with a Coulochem elec-
trode array detector, as described previously [11]. The Tmax and t1/2
values were derived by visual inspection of the plasma concentration
versus time proﬁle. The Tmax for eckol was 2 h, and the plasma concen-
tration–time curves were ﬁtted with T1/2 of 17.8 h for the plasma sam-
ples of eckol-treated mice.
2.4. Endogenous colony-forming units (CFU)
An endogenous CFU assay was performed to conﬁrm the eﬀect of
eckol (10 mg/kg b.w.) on the hematopoietic ability. The mice (n = 3
per group) were killed 10 days after exposure to 7 Gy of irradiation.
The spleens were removed and scored with naked eyes for macroscopic
colonies on the splenic surfaces [12]. The experiment was repeated
three times with a minimum of three animals in each group.
2.5. Preparation of primary splenocytes
Spleens removed from test mice were the source of single-cell suspen-
sions obtained using a cell strainer. The cells were lysed with ACK buf-
fer, which contained 0.84% ammonium chloride, for 10 min at room
temperature and washed with Dulbeccos phosphate-buﬀered saline
(DPBS, Gibco-BRL). The splenocytes were suspended in RPMI-1640
medium (Gibco-BRL) that was supplemented with 10% fetal bovine
serum (Gibco-BRL) and 100 U/ml penicillin–streptomycin (Gibco-
BRL). Cell viability was determined by trypan blue dye exclusion (Sig-
ma–Aldrich, St. Louis, MO, USA), and the puriﬁed cells (viability
>90%) were used directly in the experiments.
2.6. Alkaline comet assay
An alkaline comet assay was used to determine the oxidative DNA
damage induced in peripheral blood lymphocytes by 7 Gy of ionizing
radiation. Peripheral blood lymphocytes were isolated from the whole
blood by using Ficoll-Hypaque (Sigma–Aldrich). The basic alkaline
technique was performed as described by Kang et al. [13]. The samples
were observed under a ﬂuorescence microscope and analyzed by using
the Komet 5.5 program (Kinetic Imaging, Liverpool, UK). The
percentage of ﬂuorescence in the tail DNAs of 50 cells per slide was
recorded. DNA damage inhibition activity (%) was calculated as:
[(A  B)/A] · 100.
2.7. 3H-thymidine incorporation assay
To assess whether eckol stimulated the regeneration and prolifera-
tion of splenocytes damaged by irradiation, a thymidine incorporation
assay was performed. The splenocytes were isolated 9 days after expo-
sure to 7 Gy of irradiation and seeded at 4 · 105 cells/well in 96-well
round-bottom microtiter plates (Nunc, Copenhagen, Denmark). After
incubation in triplicate with 200 ll culture medium for 72 h at 37 C in
humidiﬁed air that contained 5% CO2, 10 ll of Concanavalin A (Con
A, Sigma) was added to the wells to give a ﬁnal concentration of 5 lg/
ml Con A. After incubation, triplicate wells for each experiment were
pulsed for a ﬁnal 18 h with 1 lCi of 3H-methylthymidine (speciﬁc
activity of 42 Ci/mmol; Amersham, Arlington Heights, IL, USA). An
automatic cell harvester gathered the cells onto glass ﬁber ﬁlters. The
amount of radioactivity incorporated into the DNA was determined
in a liquid scintillation spectrometer (MicroBeta TriLux, Perkin–El-
mer, Wallac, Germany).2.8. Flow cytometry
To deﬁne the speciﬁc cell population stimulated by eckol, the spleno-
cytes were analyzed by ﬂuorescence-activated cell sorting (FACS).
Mice were killed 9 days after exposure to 7 Gy of WBI, and their
spleens were removed. The splenocytes (1 · 106) were harvested, and
non-speciﬁc staining was inhibited by treatment with an anti-mouse
IgG (Caltag Laboratories, Burlingame, CA, USA) in PBS for 15 min
at 4 C. The cells were then stained for 15 min at 4 C with FITC-
labeled anti-CD3 (145-2C11) antibody, as a speciﬁc marker for pan T
cells, and FITC-labeled anti-CD45R/B220 (RA3-6B2) antibody, as a
speciﬁc marker for pan B cells. All the antibodies were purchased from
BD Biosciences (San Jose, CA, USA). Viable cells (20000 per mouse, as
determined by the light scattering proﬁles) were analyzed by using the
BD FACSCalibur (BD Biosciences). In the cytogram, we observed
three main clusters related to the major cell types of the spleen: lympho-
cytes, monocytes, and polymorphonuclear granulocytes. All the results
shown represent three separate experiments (n = 3).
2.9. Statistical and pharmacokinetic analyses
The results are reported as means ± S.E. or S.E.M. The results were
analyzed by using the Students t-test, and P < 0.05 or P < 0.01 was
considered statistically signiﬁcant. The plasma concentration–time
data for the eckol Tmax were analyzed using the PK Solution version
2.0 software package (Submit Research Service, Ashland, OH, USA).3. Results
3.1. Eckol improves the survival rate of mice exposed to a lethal
dose of irradiation
To test whether eckol could protect mice from radiation-
induced damages, eckol was administered at doses of 10 mg/kg
b.w. at 2 and 18 h before exposure to 8, 9, or 10 Gy of WBI.
Only 28.6% (4/14) of the irradiated, untreated group survived
for 30 days after exposure to 9 Gy of irradiation. However,
86.6% (13/15) of the mice that received eckol plus irradiation
survived for 30 days, which represents a signiﬁcantly dimin-
ished death rate (Table 1, P < 0.05). In regression analysis of
the survival data, the LD50/30 value was 8.0 Gy for the irradi-
ated, untreated control group and 9.2 Gy for the eckol plus
irradiation group, generating a dose reduction factor of 1.2
(Fig. 2). No deaths occurred in the non-irradiated group or
the eckol-only treatment group during the 30 days. These re-
sults demonstrate that eckol confers marked radioprotection
and subsequently prolongs the survival of lethally irradiated
mice.
3.2. Eckol enhances hematopoietic recovery
To conﬁrm the radioprotective eﬀect of eckol on hematopoi-
etic stem cells damaged by ionizing radiation, an endogenous
CFU assay was performed. The number of endogenous CFUs
is considered to be an indicator of hematopoiesis, which is a
Fig. 2. The radioprotective eﬀect of eckol on the survival of lethally
irradiated mice. Mice were injected i.p. with eckol (10 mg/kg b.w.) 2
and 18 h before being exposed to 9 Gy of WBI. The results shown are
the cumulative values from three independent experiments. The
numbers inserted below the percentages indicate the numbers of mice
per group.
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group and irradiation control group, the numbers of endo-
genous CFUs were 2.3 ± 0.5 and 3.5 ± 0.5, respectively
(P < 0.05) (Fig. 3). Eckol given alone did not alter the results
for the non-irradiated group (data not shown). Therefore, eck-
ol increased the number of CFUs by about 50%, indicating the
restoration of hematopoietic ability by the splenic progenitor
cells.
3.3. Eckol reduces DNA damage in lymphocytes
Given that eckol is known to have ROS scavenging activity
[8], we studied the inﬂuence of eckol on the DNA damage to
peripheral blood lymphocytes caused by ionizing radiation
using the alkaline comet assay [14]. We measured the post-irra-
diation DNA damage in the tails of eckol-treated (Fig. 4B) and
untreated control (Fig. 4C) mice, as compared to the corre-
sponding levels in non-irradiated normal mice (Fig. 4A). In
Fig. 4D, the columns contain the percentage of tail DNA
and the inhibition of activity for each group. Before irradia-
tion, the percentage of tail DNA in the lymphocytes of mice
was 8.0 ± 4.1%. In contrast, after exposure to 7 Gy of WBI,
their content of tail DNA increased to 42.5 ± 8.7%. However,Fig. 3. The eﬀect of eckol on endogenous spleen colonies of 7 Gy-irradiated
eckol-treated plus irradiated mice. (B) CFU counts on the splenic surfaces 10
i.p. 2 and 18 h before irradiation. The data represent the mean ± S.E.M.eckol treatment signiﬁcantly decreased the percentage of tail
DNA in lymphocytes damaged by irradiation to 14.7 ± 5.6%
(Fig. 4, P < 0.05).
3.4. Eckol induces splenocyte proliferation and increases the
populations of T and B cells
To deﬁne the precise cell population(s) stimulated by eckol,
murine splenocytes were analyzed by ﬂow cytometry. Three
days after irradiation, the number of lymphocytes, monocytes,
and granulocytes that had been damaged by exposure to 7 Gy
of WBI increased by 14.9%, 90.4%, and 85.6%, respectively, in
the eckol-treated mice, as compared to the untreated control
groups (Fig. 5A). Next, the proliferation of splenocytes was as-
sessed by measuring the incorporation of 3H-thymidine 9 days
after irradiation to verify the survival beneﬁt conferred by eck-
ol upon radiosensitive immune cells. As illustrated in Fig. 5B,
eckol signiﬁcantly increased the thymidine incorporation of
splenocytes, i.e., by as much as twofold in 9 days, in compar-
ison with the splenocytes of irradiated mice without eckol
treatment (P < 0.05). The background proliferation was
411 ± 92 cpm. When measured as a positive control, Con A-in-
duced proliferation was 31004 ± 4292 cpm. Additionally, the
numbers of CD3+ pan T cells and CD45R/B220+ pan B cells
increased in the eckol-treated groups, as compared to the un-
treated control groups after irradiation (Fig. 5C). In particu-
lar, the number of CD3+ T cells increased from 32.9% to
47.5%, which indicated a 44.3% increase against the untreated
controls (Fig. 5C, upper panel). Moreover, the CD45R/B220+
pan B cell population expanded from 17.2% to 21.0% (27.6%)
(Fig. 5C, lower panel). These results conﬁrm that eckol en-
hanced immunoprotection by increasing the recovery rates of
speciﬁc populations of immune cells.4. Discussion
In the present study, we demonstrate that eckol eﬀectively
protects mice against potentially lethal irradiation and pro-
longs the survival of lethally irradiated animals. The survival
time for lethally irradiated animals can be lengthened by vari-
ous manipulations, such as inhibition of free radical generation
or acceleration of their removal, enhancement of DNA repair,
replenishment of dead hematopoietic cells, and stimulation ofmice. (A) Photograph of spleens from non-irradiated, irradiated, and
days after exposure to 7 Gy of WBI. Eckol (10 mg/kg b.w.) was injected
Fig. 4. The eﬀect of eckol on DNA damage induced by irradiation of peripheral blood lymphocytes, as assessed with the alkaline comet assay. Mice
were exposed to: (A) 0 Gy of irradiation; (B) 7 Gy of irradiation; (C) 7 Gy of irradiation plus eckol treatment (10 mg/kg b.w., i.p.); (D) percentage of
ﬂuorescence in the tail DNAs and inhibition activity of each group (*P< 0.05).
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ports to date have described the protective eﬀect of eckol
against radiation-induced tissue damage or the underlying
mechanism of that eﬀect in vivo.
Radiation-induced oxidative damage to DNA encompasses
several types of base damage and single- or double-strand
breaks [16]. Using the comet assay, we observed that eckol
treatment signiﬁcantly decreased the percentage of tail
DNA ﬂuorescence in the peripheral blood lymphocytes of
irradiated mice, which indicates that eckol protected cells
against radiation-induced damage. This decrease in DNA
breakage seen in our eckol-treated, irradiated mice underlines
the cytoprotective eﬃcacy of this compound in vivo, which
may be attributed to its ROS scavenging activity [8].
These functions of eckol are likely to be factors in the pro-
longed survival of the lethally irradiated animals documented
here.
Hematopoietic stem cells are highly sensitive to ionizing
radiation as well as chemotherapeutic drugs administered to
cancer patients. In fact, myelosuppression and hematopoietic
dysfunction are the most common clinical complications of
these treatments [17]. Therefore, an important adjunct to their
use is to promote the recovery of hematopoiesis [18]. In our
experiments, mice treated with eckol recovered from WBI as
established by their increased numbers of splenic CFUs in
comparison with the irradiated controls that did not receive
eckol. The enhancement of endogenous CFUs in mice that re-
ceived eckol before undergoing irradiation indicates that eckolprotects and/or stimulates the proliferation of hematopoietic
stem cells. This important mechanism of eckol-mediated sur-
vival described here appears to have a strong potential for clin-
ical application.
Furthermore, eckol stimulated the proliferation of spleno-
cytes that had been reduced in number by irradiation and facil-
itated the repopulation of speciﬁc immune cell types, including
CD3+ (all mature T cells) and CD45R/B220+ (pan B cells)
cells. These results indicate that eckol protects against radia-
tion-induced damage by stimulating the proliferation and mat-
uration (diﬀerentiation) of immune cells. This stimulatory
eﬀect of eckol on the diﬀerentiation and maturation of T and
B cells may promote the synthesis of cytokines and antibodies.
Radiation-induced destruction of the lymphoid and hemato-
poietic systems causes bone marrow suppression and depletion
of peripheral blood lymphocytes, leading to a loss of immune
function. Subsequently, the exposed individuals become sus-
ceptible to opportunistic pathogens, some of which cause mor-
tality [19]. Therefore, the immunostimulatory potential of
eckol is an important component of its radioprotective eﬃ-
cacy.
In summary, our current results demonstrate that eckol re-
duces the mortality rate of mice exposed to a lethal dose of
WBI by accelerating hematopoietic recovery. Furthermore,
in radiosensitive immune cells, eckol enhances the repair func-
tions suppressed by ionizing radiation. Taken together, these
attributes contribute to prolonged survival after an exposure
to a potentially lethal dose of radiation. We propose that eckol
Fig. 5. Eckol contributes to the restoration of immune cell populations suppressed by ionizing radiation. Splenocytes were separated 9 days after the
mice received 7 Gy of irradiation. Eckol was administered i.p. 2 and 18 h before irradiation. (A) The columns indicate lymphocytes (a), monocytes
(b), and granulocytes (c). Each data-point represents the mean ± S.E.M. (*P < 0.05, **P < 0.01). (B) The values for proliferative responses are the
mean ± S.E.M. of cpm (*P < 0.05). (C) Phenotypic analysis of proliferating lymphocytes after eckol treatment. The expression level of each cell type
was measured by FACS using anti-CD3 and CD45R/B220 monoclonal antibodies.
E. Park et al. / FEBS Letters 582 (2008) 925–930 929is a candidate for adjuvant therapy to alleviate radiation-
induced damage to cancer patients.
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